Asclepiumm Taiwan Co., Ltd. logo

Asclepiumm Taiwan Co., Ltd.

Asclepiumm is an early stage therapeutic company deveeloping bio-therapeutic and peptide drugs, targeting cancer and eye diseases; utilizing its innovative Antibody Switch-on Cytotoxicity (ASC) platform for bio-drug delivery.

Asclepiumm platform - ASC (Antibody Switch-on Cytotoxicity) generates ASC bio-drugs which are novel antibody-peptide fusion protein drugs. Upon entering the human body, the ASC bio-drug are delivered to the surface of the target cancer cell. Proteases in the micro-environment of the target cancer cell switch-on the penetrating peptide, which creates an opportunity for cytotoxic peptide payload to escape from endocytosis and then into the cancer cell to kill it.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.asclepiumm.com
Founded2011
Disease Focus
Development StageIND Stage
STOCK CODENon Listed
Address
45, Minsheng Rd, Tamsui, 25160
New Taipei City
Taiwan
Email
Contact Number
+886-2-2809-4661 #3066

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]